

Pepinemab

| | |
|-----------|---|
| Cat. No.: | HY-P99407 |
| CAS No.: | 2097151-87-4 |
| Target: | Others |
| Pathway: | Others |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | |
|-------------|--|
| Description | Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D ^[1] . |
| In Vitro | Pepinemab(VX 15/2503) (48 h) significantly inhibits the expression of glucose transporter protein (GLUT-1) and monocarboxylate transporter protein (MCT) 4 in primary human astrocytes CC-2565 and suppresses SEMA4D-induced reduction in glucose uptake by astrocytes ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Elizabeth E Evans, et al. Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity. J Neuroinflammation. 2022 Aug 6;19(1):200.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA